

## Medication Nonadherence in AstraZeneca Psychiatry Studies, 2001-2011

Indication	Number of Subjects Receiving Active Treatment	Name of Drug Under Study	Subjects with > Half of PK Samples BLQ (%)
MDD	39	AZD2066*	12.8
MDD	91	AZD7268†	16.5
MDD	100	AZD5077†	26.0 ¶
GAD	169	AZD7325‡	22.5
GAD	309	AZD7325‡	21.7
CIAS	313	AZD3480§	20.1
MDD	331	AZD5077†	23.3 ¶
GAD	413	AZD5077†	39.2 ¶

BLQ, Below the Limit of Quantification

MDD, Major Depressive Disorder


GAD, Generalized Anxiety Disorder

CIAS, Cognitive Impairment Associated with Schizophrenia


\*Limit of Quantification (LQ) = 1.00 nmol/L. †LQ = 0.5 ng/mL. ‡LQ = 0.05 ng/mL. §LQ = 0.04 nmol/L.

¶Only one PK sample was obtained in the study.

**J Clin Psychopharm 35: 556, 2015**



■ Placebo ■ Bupropion 150 mg BID ■ Varenicline 1 mg BID ■ Lorcaserin 10 mg BID



Treatment period = 12 weeks

Success = continuous smoking abstinence, weeks 9 – 12 (no reported smoking and exhaled CO  $\leq$  10 PPM).